دورية أكاديمية

Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study.

التفاصيل البيبلوغرافية
العنوان: Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study.
المؤلفون: Lucchini, Elisa, Palandri, Francesca, Volpetti, Stefano, Vianelli, Nicola, Auteri, Giuseppe, Rossi, Elena, Patriarca, Andrea, Carli, Giuseppe, Barcellini, Wilma, Celli, Melania, Consoli, Ugo, Valeri, Federica, Santoro, Cristina, Crea, Enrico, Vignetti, Marco, Paoloni, Francesca, Gigliotti, Casimiro Luca, Boggio, Elena, Dianzani, Umberto, Giardini, Ilaria
المصدر: British Journal of Haematology; Apr2021, Vol. 193 Issue 2, p386-396, 11p
مصطلحات موضوعية: IDIOPATHIC thrombocytopenic purpura, ELTROMBOPAG, LYMPHOCYTE subsets, LONGITUDINAL method, ADULTS
مستخلص: Summary: Up to 30% immune thrombocytopenia (ITP) patients achieve a sustained remission off‐treatment (SROT) after discontinuation of thrombopoietin receptor agonists (TPO‐RAs). Factors predictive of response are lacking. Patients aged ≥18 years with newly diagnosed or persistent ITP were treated with eltrombopag for 24 weeks. Primary end‐point was SROT: the proportion of responders that were able to taper and discontinue eltrombopag maintaining the response during a period of observation (PO) of six months. Secondary end‐points included the association between some immunological parameters (TPO serum levels, cytokines and lymphocyte subsets) and response. Fifty‐one patients were evaluable. Primary end‐point was achieved in 13/51 (25%) treated patients and 13/34 (38%) patients who started the tapering. Baseline TPO levels were not associated with response at week 24 nor with SROT. Higher baseline levels of IL‐10, IL‐4, TNF‐α and osteopontin were negative factors predictive of response (P = 0·001, 0·008, 0·02 and 0·03 respectively). This study confirms that SROT is feasible for a proportion of ITP patients treated with eltrombopag. Some biological parameters were predictive of response. [ABSTRACT FROM AUTHOR]
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00071048
DOI:10.1111/bjh.17334